/wp-content/uploads/BlossomHill-Logo_FullColor.svg00David Anderson/wp-content/uploads/BlossomHill-Logo_FullColor.svgDavid Anderson2026-01-05 07:02:032026-01-05 07:02:03BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-12-09 12:48:152025-12-09 15:30:48BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00David Anderson/wp-content/uploads/BlossomHill-Logo_FullColor.svgDavid Anderson2025-11-03 08:15:482025-12-09 12:48:53BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-10-23 16:49:222025-10-29 08:20:27BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00Steve Klass/wp-content/uploads/BlossomHill-Logo_FullColor.svgSteve Klass2025-10-14 04:02:112025-10-14 08:14:42BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-08-22 14:06:152025-08-22 14:06:15BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-05-09 10:43:032025-05-09 10:43:03BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-04-02 16:56:432025-04-03 05:04:22BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-01-22 10:50:142025-01-22 13:14:15BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer
/wp-content/uploads/BlossomHill-Logo_FullColor.svg00eallison/wp-content/uploads/BlossomHill-Logo_FullColor.svgeallison2025-01-03 12:01:552026-01-05 07:30:34BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.